Aardvark Therapeutics posted a Q2 net loss of $14.4 million, while cash and short‑term investments total $73.9 million, enough to fund operations into late 2027. The loss underscores lingering clinical setbacks, but the cash runway gives investors breathing room while the company seeks to resolve the FDA hold on its ARD‑101 program.

Key Highlights

  • AARD reported EPS of $‑0.99 versus consensus $‑0.89, widening the loss gap.
  • R&D expenses fell to $10.5 million, a $2.6 million drop from the prior year.
  • Cash and short‑term investments fell to $73.9 million as of June 30 2026, down from $91.2 million three months earlier, but are projected to fund operations into late 2027.
  • R&D expenses decreased to $10.5 million year‑over‑year, while G&A costs rose to $4.6 million, reflecting a shift in cost structure after the voluntary pause of ARD‑101 trials.

The cash balance, down from $91.2 million three months earlier, is projected to sustain operations through late 2027.

Q2 Financial Outcome

Research and development expenses declined to $10.5 million from $13.1 million a year earlier, largely driven by a $3.3 million cut in external CMC, clinical and toxicology costs after the voluntary pause of all ARD‑101 trials. General and administrative costs rose to $4.6 million from $2.7 million, reflecting higher personnel spend and a $0.5 million severance bill. The tighter expense profile offsets some of the loss, yet the Bottom Line remains unchanged.

This expense shift shows how the clinical hold directly reshapes the cost structure.

Cash Position and Runway

Cash and short‑term investments stood at $73.9 million as of June 30, 2026, a decline from $91.2 million three months prior. Management believes this reserve will fund projected operations into late 2027, granting the firm a runway that exceeds one full year despite the halted ARD‑101 program. The cash cushion is critical for a biotech still seeking regulatory clarity, as it must finance the unblinded data assessment for HERO and OLE trials while negotiating with the FDA.

Maintaining sufficient Liquidity reduces financing risk, but the diminishing balance signals the need for future Capital if trials resume.

Clinical Hold and Market Sentiment

In May 2026, the FDA imposed a full clinical hold on the IND for ARD‑101, following a voluntary pause of the HERO and OLE studies. The company terminated these trials in June 2026 and now focuses on analyzing unblinded data to determine next steps. Investor sentiment reflects this tension: the stock’s 45.5% YTD decline signals skepticism, yet the 20.6% monthly gain shows renewed optimism as the firm prepares to disclose HERO results.

The hold intensifies uncertainty, but the cash runway offers investors a buffer while the outcome of the data review unfolds.

Upcoming Catalyst

Aardvark plans to evaluate unblinded HERO and OLE data in the third quarter of 2026, a review that will shape future development decisions for ARD‑101. Management’s discussions with the FDA remain active, and any resolution of the clinical hold could materially alter the company’s trajectory. The next Earnings release, expected later in the year, will likely incorporate updates on the data assessment and potential trial resumption, providing a key market signal for investors.